Anterogen.Co.Ltd (065660.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7065660003

Price
13,600.00 KRW
Market cap
136.08 bn KRW
P/E (2025)
–
P/S (2025)
18.06
Dividend yield
0.00 %
Net margin
-18.23 %
Return on equity (ROE)
-1.57 %
Return on assets (ROA)
-1.56 %

Anterogen.Co.Ltd financials

Fiscal year20242025
Revenue6.93 bn KRW7.54 bn KRW
Gross profit2.63 bn KRW2.66 bn KRW
Operating income-3.80 bn KRW-2.43 bn KRW
EBIT-2.03 bn KRW-2.43 bn KRW
Net income-2.29 bn KRW-1.37 bn KRW
Diluted EPS – continuing operations-235.61 KRW-137.30 KRW

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Anterogen.Co.Ltd

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.